Evommune (NYSE:EVMN) Insider Sells $324,711.09 in Stock

Evommune, Inc. (NYSE:EVMN) insider Gregory Moss sold 14,223 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $22.83, for a total transaction of $324,711.09. Following the sale, the insider owned 60,835 shares of the company’s stock, valued at $1,388,863.05. The trade was a 18.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Evommune Stock Down 5.1%

Shares of Evommune stock traded down $1.20 on Monday, hitting $22.04. 451,405 shares of the company’s stock traded hands, compared to its average volume of 416,057. The firm has a 50-day moving average price of $24.14. The company has a market cap of $793.70 million and a PE ratio of -2.32. Evommune, Inc. has a one year low of $13.89 and a one year high of $33.20.

Evommune (NYSE:EVMN) last issued its earnings results on Thursday, May 7th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.19. Research analysts expect that Evommune, Inc. will post -2.83 earnings per share for the current year.

Institutional Trading of Evommune

A number of large investors have recently made changes to their positions in EVMN. Perceptive Advisors LLC bought a new position in Evommune during the 1st quarter worth about $10,308,000. Bank of America Corp DE boosted its stake in shares of Evommune by 928.3% during the 1st quarter. Bank of America Corp DE now owns 30,201 shares of the company’s stock worth $694,000 after buying an additional 27,264 shares during the last quarter. Stempoint Capital LP boosted its stake in shares of Evommune by 184.1% during the 1st quarter. Stempoint Capital LP now owns 193,777 shares of the company’s stock worth $4,385,000 after buying an additional 125,581 shares during the last quarter. Janus Henderson Group PLC acquired a new position in shares of Evommune during the 1st quarter worth about $20,615,000. Finally, Eversept Partners LP acquired a new position in shares of Evommune during the 1st quarter worth about $1,257,000.

Wall Street Analysts Forecast Growth

Several brokerages have commented on EVMN. Clear Str upgraded shares of Evommune to a “strong-buy” rating in a research report on Tuesday, March 17th. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Evommune in a research report on Tuesday, May 26th. Royal Bank Of Canada reiterated an “outperform” rating and set a $48.00 target price on shares of Evommune in a research report on Friday, April 10th. Weiss Ratings began coverage on shares of Evommune in a research report on Tuesday, February 3rd. They set a “sell (e)” rating for the company. Finally, Wall Street Zen upgraded shares of Evommune from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. Three investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $49.25.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.